Reagents & kits

Base editors (CBE/ABE) make precise C·G→T·A and A·T→G·C point substitutions without double-strand breaks — treating monogenic diseases (sickle cell disease, beta-thalassemia) with up to 90% efficiency and no indels.

Maker and classroom kits that turn a human or animal bioelectric signal into readable electronic data — the electrical-signal counterpart to the microbial and DNA kits elsewhere in this catalogue.

Bioluminescence and marine fluorescent proteins form the instrument base for real-time imaging of biological processes: luciferin-luciferase systems that emit light without external excitation, and fluorescent proteins that re-emit absorbed light at a longer wavelength.

Non-invasive breath analysis using VOC patterns for early disease diagnosis and continuous monitoring.

Tissue-based immunohistochemistry (IHC) and FISH platforms that determine whether a given patient is a fit for a given targeted therapy, sold and regulated as a companion diagnostic (CDx) tied directly to the drug label.

Cas-enzyme nucleic-acid detection — bedside-to-strip molecular diagnostics from sample to paper strip.

Classroom and community-lab kits that let students run a real or simulated CRISPR-Cas9 genome-editing process — a category distinct from cheaper cheek-cell DNA-extraction kits that don't touch genome editing.

CRISPR screening as a service — high-throughput functional-genetics discovery of targets and resistance mechanisms in mammalian cells: pooled guide-RNA libraries that knock out, activate or suppress thousands of genes, followed by deep sequencing and bioinformatic analysis.

Advanced analytical devices that detect biological markers for rapid, accurate disease identification and monitoring.

Direct-to-consumer (DTC) genetic testing from saliva via SNP chip genotyping and 30x whole-genome sequencing, with bioinformatic polygenic-risk scoring and telehealth gating of pathogenic findings (BRCA1/2), operating under FDA 510(k), EU IVDR and China's genetic-data sovereignty rules.

Reading DNA methylation patterns across hundreds of thousands of CpG sites to calculate a person's biological age and rate of ageing instead of birth-certificate chronological age, turning a $229-799 saliva or blood test into the longevity industry's core diagnostic tool.

Switching genes on or off by rewriting DNA methylation and histone marks using dCas9 or zinc-finger fusion proteins — without changing the DNA sequence, but with an effect inherited across cell divisions.

Non-invasive exhaled-breath analysis devices targeting diabetes-relevant metabolic-state monitoring without a finger prick or implanted sensor — all US-based.

Programmable genome editors — CRISPR-Cas9, base and prime editors — delivered ex vivo or in vivo in lipid nanoparticles to treat genetic disease: from the first approved CRISPR therapy Casgevy to redosable in-vivo…

Sequencing-based services that track pathogen genomic evolution and spread for healthcare-system response — border/airport biosurveillance, portable field sequencing and national metagenomic surveillance programmes.

Self-collected blood sampling for consumer health testing — mailed to a certified lab or dropped at a retail micro-collection point.

The shared substrate synthetic biology runs on: the standard-parts registry and the student competition that populates it, non-profit plasmid repositories, commercial gene synthesis now reaching 7,000 base pairs on…

Surgically or subcutaneously implantable sensors that continuously track a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and implantable cardiac monitors.

Swallowable capsule devices that image the GI tract or confirm medication ingestion as they pass through the body, requiring no sedation or implantation.

Synthetic genetic circuits that make engineered organisms dependent on an external chemical signal to survive, self-destruct or lose viability once released into the environment.

Real-time molecular and optical tissue identification right in the operating room — fluorescent imaging agents, OCT, stimulated Raman histology and mass-spectrometry tissue analysis.

Detecting and quantifying circulating tumour DNA (ctDNA) in blood for companion oncology diagnostics and minimal-residual-disease (MRD) monitoring, replacing or supplementing tissue biopsy.

Microbiome diagnostic panels sequence and analyze microbial communities from a stool or swab sample — from consumer wellness testing to clinical pathogen and dysbiosis detection.

The frontier of building life de novo — reducing genomes to a minimal viable chassis (top-down) and assembling artificial cells from non-living components (bottom-up) for predictable, bio-isolated cell factories.

Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types — a population-screening scenario distinct from companion-therapy diagnostics.

Integrative genomic, transcriptomic and proteomic oncology-profiling platforms that combine multiple layers of molecular data into a single therapy-matching report.

Next-generation-sequencing-based forensic DNA analysis that predicts appearance and biogeographic ancestry from crime-scene DNA, or matches it against public genealogy databases to generate investigative leads.

Outsourced One Health surveillance combining veterinary, human and environmental sampling with shotgun metagenomic sequencing, CARD-based resistome profiling and AI cross-species spillover risk scoring to detect zoonotic pathogens and antibiotic resistance.

Microphysiological systems that mimic human organs in vitro, to replace animal testing and accelerate personalized medicine.

Molecular diagnostics using NGS, liquid biopsy and AI for precision medicine and targeted therapy.

Point-of-care molecular diagnostics run nucleic-acid testing outside the central lab — in a clinic, emergency department or field site — delivering an on-site result without sending samples away.

Search-and-replace genome editing: a Cas9 nickase fused to reverse transcriptase, paired with an extended pegRNA, writes all 12 base substitutions plus small insertions/deletions without a double-strand break.

Rapid antibiotic-resistance tests determine which antibiotics a given pathogen is susceptible or resistant to, substantially faster than classical culture-based susceptibility testing.

Authenticated type strains of microorganisms and WHO biological reference materials.

Eye-scanning technologies that detect Alzheimer's and other neurodegenerative disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself.

Engineering biology — designing DNA, cells and genetic circuits on a computer, assembling them in a biofoundry, and scaling them into chemicals, materials and ingredients through a Design-Build-Test-Learn cycle.

Engineered exogenous reporter molecules — activatable nanosensors, synthetic gene circuits and volatile-organic-compound probes.

Tear fluid biopsy analyzes microliter volumes of tears for markers of dry eye, ocular allergy and inflammation — a diagnostic window that entirely avoids blood draws and invasive procedures.

Direct DNA testing for dogs and cats — a stack running from cheek-swab collection to an LIMS-verified veterinary genetic passport screening hundreds of hereditary risks.

Aggregated, non-invasive molecular monitoring of municipal sewage to detect pathogens, antibiotic resistance and psychoactive substances — an early public-health warning service based on virus concentration, digital droplet PCR and metagenomic sequencing.

Wearable biodiagnostics and continuous monitoring systems delivering real-time precision health management.

Orthogonal biological systems based on xeno nucleic acids, non-canonical base pairs and genomically recoded organisms that incorporate non-canonical amino acids into proteins — enabling site-specific drug conjugation and a genetic firewall against horizontal gene transfer to wild species.